5月9日,阿斯利康宣布Imfinzi(度伐利尤单抗)联合标准治疗(SOC)治疗高危非肌层浸润性膀胱癌(NMIBC)患者的III期POTOMAC研究取得了积极的高水平结果。该研究是一项随机、开放标签、多中心、全球性临床试验(n=1018),评估了Imfinzi联合卡介苗(BCG)治疗接受过经尿道膀胱肿瘤切除术(TURBT)但未接受过BCG治疗的高危NMIBC患者的疗效和安全性。患者被随机平均分为三组...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.